Atyr PHARMA (NASDAQ:ATYR - Get Free Report)'s stock had its "buy" rating restated by investment analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $35.00 price objective on the stock.
A number of other analysts also recently issued reports on ATYR. Cantor Fitzgerald initiated coverage on Atyr PHARMA in a report on Monday, January 6th. They set an "overweight" rating for the company. Leerink Partners started coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price for the company. Finally, Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $18.60.
Read Our Latest Report on ATYR
Atyr PHARMA Stock Down 0.5 %
NASDAQ ATYR traded down $0.02 during trading on Friday, reaching $3.97. 2,401,773 shares of the company's stock were exchanged, compared to its average volume of 1,313,086. The stock has a market cap of $333.25 million, a P/E ratio of -4.22 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The company has a 50 day moving average price of $3.65 and a two-hundred day moving average price of $3.07. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. On average, equities research analysts anticipate that Atyr PHARMA will post -0.91 EPS for the current fiscal year.
Hedge Funds Weigh In On Atyr PHARMA
Institutional investors have recently added to or reduced their stakes in the stock. Group One Trading LLC acquired a new position in Atyr PHARMA in the 4th quarter valued at about $26,000. Alterna Wealth Management Inc. acquired a new position in Atyr PHARMA in the 4th quarter valued at about $36,000. Victory Capital Management Inc. acquired a new position in Atyr PHARMA in the 4th quarter valued at about $37,000. Raymond James Financial Inc. acquired a new position in Atyr PHARMA in the 4th quarter valued at about $39,000. Finally, XTX Topco Ltd acquired a new position in Atyr PHARMA in the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 61.72% of the company's stock.
Atyr PHARMA Company Profile
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Further Reading
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
